Not Tagged
turning point therapeutics,bms
['lung', 'sclc', 'nsclc', 'solid tumor', 'bms', 'tptherapeutics']
san diego's precision oncology acquired by bms at $4.1b &amp; repotrectinib targets ros1 &amp; ntrk oncogenic drivers of non-small cell lung cancer (nsclc) &amp; other advanced solid tumors.comments by bms cmo &amp; evp elizabeth mily #asco22 
Founder of Cambridge BioPartners, Inc. I'm also @PearlF on Clubhouse.